Simultaneous Analysis of Remogliflozin Etabonate and Vildagliptin in Tablets by HPTLC: Method Development and Validation

Recently, Vildagliptin and Remogliflozin together have become a viable treatment choice for diabetes. The invention of HPTLC (High Performance Thin Layer Chromatography) approach for the concurrent measurement of Vildagliptin (VILG) and Remogliflozin (REMO) in both their pure API (Active Pharmaceutical Ingredient) forms and in a commercially accessible formulation is shown in the present work. The method is robust, selective, sensitive, and fast. Utilizing a solvent solution consisting of toluene: ethyl acetate: methanol and glacial acetic acid (2.0: 6.0: 0.5: 0.1, v/v/v/v), the separation was successfully accomplished on silica gel F254. The chromatographic bands were observed at a wavelength of 250nm in short-wave ultraviolet light. With retention factor Rf values of 0.36 and 0.71 for REMO and VILG, correspondingly, proposed method showed clearly delineated spots.